We speculate that under these conditions, Mcl-1 inhibitor A-1210477 may act as a senolytic compound able to eradicate imatinib-sensitive and resistant CML cells. The gene discussed is MCL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.